Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02244372
Recruitment Status : Completed
First Posted : September 19, 2014
Last Update Posted : August 22, 2019
Sponsor:
Information provided by (Responsible Party):
Soo-Wan Chae, Chonbuk National University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) on promotion of immunity. The investigators measured promotion of immunity parameters , including Cytotoxicity, Cytokine (IL-4, IL-6, IL-12, IFN-γ, TNF-α), hs-CRP, antibody titer, and upper respiratory tract infection(URI)

Condition or disease Intervention/treatment Phase
Immunity Dietary Supplement: Cordyceps sinensis mycelium culture extract 0.76 g Dietary Supplement: Cordyceps sinensis mycelium culture extract 1.15 g Dietary Supplement: Placebo Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A 8-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
Study Start Date : September 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : February 2015
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cordyceps sinensis mycelium culture extract 0.76 g
Cordyceps sinensis mycelium culture extract 0.76 g
 Dietary Supplement: Cordyceps sinensis mycelium culture extract 0.76 g
Experimental: Cordyceps sinensis mycelium culture extract 1.15 g
Cordyceps sinensis mycelium culture extract 1.15 g
 Dietary Supplement: Cordyceps sinensis mycelium culture extract 1.15 g
Placebo Comparator: Placebo
Placebo
 Dietary Supplement: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in Cytotoxicity [ Time Frame: 4, 8 weeks ]

    Cytotoxicity was measured in study visit 1(0 week), visit 2(4 week) and visit 3(8 week). cytotoxicity was measured by NK cell activity.

    Cytotoxicity (%) = (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100



Secondary Outcome Measures :
  1. Changes in Cytokine(IL-4, IL-6, IL-12, IFN-γ, TNF-α) [ Time Frame: 4, 8 weeks ]
    Cytokine(IL-4, IL-6, IL-12, IFN-γ, TNF-α) was measured in study visit 1(0 week), visit 2(4 week), and visit 3(8 week).

  2. Changes in hs-CRP [ Time Frame: 4, 8 weeks ]
    hs-CRP was measured in study visit 1(0 week), visit 2(4 week) and visit 3(8 week).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females 20-80 years old
  • Who had suffered more than twice Upper respiratory infection* disorder or common cold causing URI
  • Able to give informed consent

Exclusion Criteria:

  • WBC concentration below 3000 ㎕
  • Subjects vaccinated against influenza within the last 6 months prior to the study
  • Subjects with Upper respiratory infection at screening visit
  • Subjects with BMI < 18.5 kg/m2 at screening visit
  • Allergic or hypersensitive to any of the ingredients in the test products
  • Diagnosed of gastrointestinal disease such as Immune-related diseases, severe hepatic, renal failure, and diabetes
  • History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • History of alcohol or substance abuse
  • Participation in any other clinical trials within past 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • Pregnant or lactating women etc.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02244372


Locations
Layout table for location information
Korea, Republic of
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, Korea, Republic of, 560-822
Sponsors and Collaborators
Chonbuk National University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Soo-Wan Chae, Principal Investigator, Clinical Trial Center for Functional Foods, Chonbuk National University Hospital
ClinicalTrials.gov Identifier: NCT02244372    
Other Study ID Numbers: CHE-PI-CM
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: August 22, 2019
Last Verified: August 2019
Keywords provided by Soo-Wan Chae, Chonbuk National University Hospital:
Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2)
immunity